Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Win McNamee/Getty Images

President Trump has called an experimental coronavirus therapy he received "a gift from Heaven" and promised to make it widely available — igniting yet another round of concern about politics encroaching on science.

What they're saying: "We have an emergency use authorization that I want to get signed immediately," Trump said in a video Thursday.

The big picture: "The problem is every therapy for coronavirus has become politicized — every single therapy, and that's the last thing you want in a pandemic, so this is just next in line," Walid Gellad, director of the Center for Pharmaceutical Policy and Prescribing at the University of Pittsburgh, told the Washington Post.

Trump is talking about a cocktail of laboratory-made antibodies made by Regeneron that he received as part of a host of medications over the past week.

  • Regeneron and Eli Lilly, which is developing a similar therapy, both applied for an emergency use authorization from the FDA this week.
  • Regeneron has said that it would have about 300,000 doses of the drug available in the next few months, and Eli Lilly will have about 1 million doses ready by the end of the year, per the Post.
  • That means that even if the drugs are quickly authorized, the number of patients who can receive them will be limited.

Between the lines: The drugs, while promising, are still undergoing clinical trials, and it's unclear whether the Regeneron therapy was responsible for Trump's apparent recovery.

What to watch: "The science of antibody drugs could ... devolve into another political dispute."

  • "But the FDA should and will weigh the benefits of the therapy against the risks and judge the application on the scientific merits, hopefully without political interference," former FDA commissioners Scott Gottlieb and Mark McClellan wrote in a Wall Street Journal op-ed yesterday.

Go deeper

L.A. becomes first county to surpass 1 million coronavirus cases

COVID-19 mass-vaccination of healthcare workers takes place at Dodger Stadium. Photo: Irfan Khan/Los Angeles Times via Getty Images

Los Angeles County officials said Saturday they had detected the county's first case of the highly transmissible coronavirus variant first found in the United Kingdom.

Why it matters: The announcement came as L.A. became the first county to surpass 1 million COVID-19 cases, straining the area's already overwhelmed health care system.

Bryan Walsh, author of Future
1 hour ago - Health

Public health messaging lessons for the next pandemic

Illustration: Megan Robinson/Axios

"Be first, be right, be credible" is the mantra of public health experts in a crisis. It's difficult to argue that the health community has regularly managed to be any of those three during COVID-19.

Why it matters: A pandemic isn't just a medical emergency — it's also a communications emergency. The U.S. public health establishment, hamstrung by bad data and political interference, has struggled with the latter.

How Hertz is fighting to stay relevant

A Hertz car rental counter in the Miami International Airport. (Photo by Joe Raedle/Getty Images)

In the span of less than a week, Hertz has made three big strategic moves intended to keep the car rental giant from fading into oblivion.

Why it matters: Ride-hailing and other mobility innovations are rapidly changing the way people get from A to B, posing an existential threat to traditional car rental services.